Science Explorer Back to mapMap
Discussion
Researcher · Saitama Cancer Center · Japan

Hideaki Mizutani

Hideaki Mizutani publishes mostly in Pulmonary and Respiratory Medicine, Oncology and Molecular Biology, on topics such as Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers and Lung Cancer Research Studies.

OpenAlex
World rank
#1,321,878
of 7,710,434 ranked researchers
Rank in Japan
#19,918
of 383,136
Works
51
Citations
1.4k
Citations per work
28.1
h-index
15
i10-index 19Top 31% in Pulmonary and Respiratory Medicine
Hideaki Mizutani

What does Hideaki Mizutani research?

Hideaki Mizutani's work is mostly in Medicine (74%), Biochemistry, Genetics and Molecular Biology (14%).

Health Sciences: 38 works · 73.9% of their workMedicine: 38 works · 73.9% of their workPulmonary and Respiratory Medicine: 18 works · 34.5% of their workOncology: 17 works · 32.4% of their workSurgery: 2 works · 4.2% of their workRadiology, Nuclear Medicine and Imaging: 1 works · 2.8% of their workLife Sciences: 7 works · 14.1% of their workBiochemistry, Genetics and Molecular Biology: 7 works · 14.1% of their workMolecular Biology: 4 works · 8.5% of their workCancer Research: 3 works · 5.6% of their workEverything else: 6 works · 12.0% of their workTHEIR WORKHideaki Mizutani51works
Life Sciences14%Health Sciences74%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Medicine3873.9%
    1. Biochemistry, Genetics and Molecular Biology714.1%
  3. Everything else612.0%
  1. 1Pulmonary and Respiratory Medicine34% of their works
  2. 2Oncology32% of their works
  3. 3Molecular Biology8% of their works
  4. 4Cancer Research6% of their works
  5. 5Surgery4% of their works
  6. 6Radiology, Nuclear Medicine and Imaging3% of their works

Research topics

Which keywords describe Hideaki Mizutani's research?

The keywords of their largest research topics: Clinical Trials, Targeted Therapy, Chemotherapy, ALK Inhibitors, EGFR Mutations, Immune Checkpoint Blockade, PD-1 and PD-L1 and Immunotherapy.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 20 words, with their numbers
  1. Clinical Trials372 topics
  2. Targeted Therapy372 topics
  3. Chemotherapy314 topics
  4. ALK Inhibitors261 topic
  5. EGFR Mutations261 topic
  6. Immune Checkpoint Blockade201 topic
  7. PD-1 and PD-L1201 topic
  8. Immunotherapy152 topics
  9. Genomic Profiles111 topic
  10. Small-Cell Lung Cancer111 topic
  11. CT Screening101 topic
  12. Lung Cancer101 topic
  13. Cetuximab61 topic
  14. KRAS Mutations61 topic
  15. Brain Metastases41 topic
  16. Cisplatin41 topic
  17. Nephrotoxicity41 topic
  18. Postoperative Nausea41 topic
  19. Radiosurgery41 topic
  20. Vomiting Prevention41 topic

Where does Hideaki Mizutani work?

Hideaki Mizutani's main affiliation in the publication record is Saitama Cancer Center, Japan.

How many publications and citations does Hideaki Mizutani have?

OpenAlex counts 51 works and 1,431 citations for Hideaki Mizutani, an h-index of 15, ranking #1,321,878 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Other researchers named Hideaki Mizutani

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Hideaki Mizutani. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.